Back to Journals » Transplant Research and Risk Management » Volume 2

Critical appraisal on the use of everolimus in renal transplantation as an immunosuppressant to prevent organ transplant rejection

Authors Giron F, Baez Y

Published 21 January 2010 Volume 2010:2 Pages 11—14

DOI https://doi.org/10.2147/TRRM.S5135

Review by Single anonymous peer review

Peer reviewer comments 3

Download Article [PDF] 

Fernando Giron, Yenny Baez

Kidney Transplant Service, Colombiana de Trasplantes, Bogota, Colombia

Abstract: Everolimus is a proliferation inhibitor designed to target chronic allograft nephropathy including prevention of acute rejection. Acute renal allograft rejection incidence varies with the therapy used for immunosuppression. Registry data show that 15% to 35% of kidney recipients will undergo treatment for at least one episode of acute rejection within the first post-transplant year. Everolimus has been used as therapy with full- or reduced-dose cyclosporine A without evidence of increasing the acute rejection incidence. This review will summarize the available clinical trial data on the use of everolimus and its role in preventing acute rejection incidence in renal transplantation.

Keywords: calcineurin inhibitors, cyclosporine, everolimus, biopsy-proven acute rejection, renal transplantation, acute rejection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]